Buprenorphine for Depression and Anxiety
丁丙诺啡治疗抑郁和焦虑
基本信息
- 批准号:8451367
- 负责人:
- 金额:$ 38.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAcuteAgonistAnimal BehaviorAnimal ModelAnimalsAnti-Anxiety AgentsAntidepressive AgentsAnxietyAnxiety DisordersAreaAttentionBehaviorBehavioralBrainBrain regionBrain-Derived Neurotrophic FactorBuprenorphineC57BL/6 MouseChronicClinicalClinical ResearchClinical TreatmentClinical TrialsDataDevelopmentDiseaseDopamineDrug InteractionsDynorphinsEffectivenessFoundationsGeneticGenetic ModelsGoalsHippocampus (Brain)Inbred WKY RatsLigandsMajor Depressive DisorderMedicalMental DepressionMental disordersMicrodialysisModelingMorbidity - disease rateMusNucleus AccumbensOpioidOpioid ReceptorPatientsPatternPharmaceutical PreparationsPhysical DependencePopulationPublic HealthPublishingRat StrainsRattusRefractoryResearchResistanceRoleSprague-Dawley RatsStressSwimmingTestingTherapeuticTranslatingapproach behaviorbasebehavior testclinical efficacyconventional therapydrug rewardeconomic impactextracellularin vivokappa opioid receptorsmu opioid receptorsneural circuitneurobehavioralneurogenesispre-clinicalprogramsprospectiveresearch studyresponsescreeningsocialtreatment effect
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this research program is to evaluate the therapeutic potential for buprenorphine and to use animal studies to support its development for depression and anxiety disorders. There is a clear medical need for new drugs that would expand the options for treating comorbid depression and anxiety, especially for the substantial number of patients' refractory to current medications. Buprenorphine is medically available and used safely for the treatment of physical dependence to opioids but has received virtually no attention for the use of psychiatric disorders in nondependent populations. As a mu-opioid receptor (MOR) partial agonist and kappa-opioid receptor (KOR) antagonist, buprenorphine has been studied extensively in models of drug reward, physical dependence, and analgesia. Recent studies highlighting the role of dynorphin in stress have shown that KOR antagonists can produce antidepressant and anxiolytic effects in animal models. The pharmacological profile of buprenorphine as a potent MOR partial agonist and KOR antagonist supports the likelihood that buprenorphine would produce beneficial effects on stress-induced behaviors. Few published studies on the effects of buprenorphine in animal models of depression and anxiety exist to support clinical trials and development or to understand its potential mechanism of action. Taken together, these experiments will establish a basic foundation for considering the development of buprenorphine for new indications in psychiatric disorders and translate to prospective clinical treatment studies of depression and anxiety in treatment-resistant patients.
描述(由申请人提供):该研究计划的总体目标是评估丁丙诺啡的治疗潜力,并利用动物研究来支持其治疗抑郁症和焦虑症的开发。显然,医学上需要新药来扩大治疗抑郁症和焦虑症共病的选择,特别是对于大量对当前药物耐药的患者。丁丙诺啡在医学上是可用的,并且可以安全地用于治疗对阿片类药物的身体依赖,但在非依赖性人群中使用丁丙诺啡来治疗精神疾病几乎没有受到关注。作为 mu-阿片受体 (MOR) 部分激动剂和 kappa-阿片受体 (KOR) 拮抗剂,丁丙诺啡已在药物奖赏、身体依赖性和镇痛模型中得到广泛研究。最近强调强啡肽在应激中的作用的研究表明,KOR 拮抗剂可以在动物模型中产生抗抑郁和抗焦虑作用。丁丙诺啡作为有效的 MOR 部分激动剂和 KOR 拮抗剂的药理学特征支持丁丙诺啡对应激诱导行为产生有益影响的可能性。很少有关于丁丙诺啡在抑郁和焦虑动物模型中的影响的已发表的研究来支持临床试验和开发或了解其潜在的作用机制。总而言之,这些实验将为考虑开发丁丙诺啡用于精神疾病新适应症奠定基础,并转化为针对难治性患者抑郁和焦虑的前瞻性临床治疗研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IRWIN LUCKI其他文献
IRWIN LUCKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IRWIN LUCKI', 18)}}的其他基金
Kappa Receptor Antagonists as Rapid Acting Antidepressants
Kappa 受体拮抗剂作为速效抗抑郁药
- 批准号:
9030490 - 财政年份:2016
- 资助金额:
$ 38.4万 - 项目类别:
Kappa Receptor Antagonists as Rapid Acting Antidepressants
Kappa 受体拮抗剂作为速效抗抑郁药
- 批准号:
9753367 - 财政年份:2016
- 资助金额:
$ 38.4万 - 项目类别:
Regulation of Hippocampal Neurogenesis by Antidepressants
抗抑郁药对海马神经发生的调节
- 批准号:
8111695 - 财政年份:2010
- 资助金额:
$ 38.4万 - 项目类别:
Regulation of Hippocampal Neurogenesis by Antidepressants
抗抑郁药对海马神经发生的调节
- 批准号:
8471195 - 财政年份:2010
- 资助金额:
$ 38.4万 - 项目类别:
Regulation of Hippocampal Neurogenesis by Antidepressants
抗抑郁药对海马神经发生的调节
- 批准号:
7987729 - 财政年份:2010
- 资助金额:
$ 38.4万 - 项目类别:
Regulation of Hippocampal Neurogenesis by Antidepressants
抗抑郁药对海马神经发生的调节
- 批准号:
8267123 - 财政年份:2010
- 资助金额:
$ 38.4万 - 项目类别:
REGULATION OF HIPPOCAMPAL NEUROGENESIS BY ANTIDEPRESSANTS
抗抑郁药对海马神经发生的调节
- 批准号:
7914988 - 财政年份:2009
- 资助金额:
$ 38.4万 - 项目类别:
相似海外基金
Elucidation of acute poisoning mechanism due to abuse of CB1 receptor agonist.
阐明滥用 CB1 受体激动剂引起的急性中毒机制。
- 批准号:
21K17323 - 财政年份:2021
- 资助金额:
$ 38.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of acute poisoning mechanism due to abuse of CB1 receptor agonist.
阐明滥用 CB1 受体激动剂引起的急性中毒机制。
- 批准号:
19K19485 - 财政年份:2019
- 资助金额:
$ 38.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Tissue repair effect in acute myocardial infarction through mobilization of endogenous Muse cells by sphingosine-1-phosphate receptor 2 agonist
1-磷酸鞘氨醇受体2激动剂动员内源性Muse细胞对急性心肌梗死的组织修复作用
- 批准号:
18K15843 - 财政年份:2018
- 资助金额:
$ 38.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6115624 - 财政年份:1998
- 资助金额:
$ 38.4万 - 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6219539 - 财政年份:1998
- 资助金额:
$ 38.4万 - 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6276858 - 财政年份:1997
- 资助金额:
$ 38.4万 - 项目类别:
ACUTE CHRONIC HORMONAL CHANGES WITH LHRH-AGONIST THERAPY
LHRH 激动剂治疗引起的急性慢性荷尔蒙变化
- 批准号:
6250152 - 财政年份:1997
- 资助金额:
$ 38.4万 - 项目类别:
ACUTE CHRONIC HORMONAL CHANGES WITH LHRH-AGONIST THERAPY
LHRH 激动剂治疗引起的急性慢性荷尔蒙变化
- 批准号:
6279945 - 财政年份:1997
- 资助金额:
$ 38.4万 - 项目类别:
EFFECT OF ACUTE E PROSTAGLANDIN AGONIST N BAL EICO
急性 E 型前列腺素激动剂 N BAL EICO 的作用
- 批准号:
6246787 - 财政年份:1997
- 资助金额:
$ 38.4万 - 项目类别:
PSYCHOPHARMACOLOGY OF DA AGONIST CNS EFFECTS: ACUTE AND CHRONIC STUDIES
DA 激动剂中枢神经系统影响的精神药理学:急性和慢性研究
- 批准号:
3891471 - 财政年份:
- 资助金额:
$ 38.4万 - 项目类别: